



26 **Abstract**

27 Timely and accurate detection of SARS-CoV-2 variants of concern (VOCs) is  
28 urgently needed for pandemic surveillance and control. However, current methods are  
29 limited by the low sensitivity, long turn-around time or high cost. Here, we report a  
30 nucleic acid testing-based method aiming to detect and discriminate SARS-CoV-2  
31 VOCs by combining RT-RPA and CRISPR-Cas12a detecting assays (RRCd). With a  
32 detection limit of 10 copies RNA/reaction, RRCd was validated in 204 clinical  
33 samples, showing 99% positive predictive agreement and 100% negative predictive  
34 agreement, respectively. Critically, using specific crRNAs, representatives of single  
35 nucleotide polymorphisms and small deletions in SARS-CoV-2 VOCs including  
36 N501Y, T478K and  $\Delta$ H69-V70 were discriminated by RRCd, demonstrating 100%  
37 accuracy in clinical samples with  $C_t < 33$ . The method completes within 65 min and  
38 could offer visible results without using any electrical devices, which may facilitate  
39 point-of-care testing of SARS-CoV-2 and its variants.

40

41 **Keywords**

42 SARS-CoV-2, variant of concern, RRCd, point-of-care testing, CRISPR

## 43 **Introduction**

44 The pandemic of COVID-19 has caused 494.5 million infections and 6.1 million  
45 deaths as of April 10<sup>th</sup> 2022 (<https://covid19.who.int/table>). The pathogen of this  
46 pandemic, SARS-CoV-2, has undergone rapid and constant mutations in the process  
47 of transmissions, bringing worldwide uncertainty to the diagnostics, vaccine  
48 effectiveness and therapeutics (Tao et al. 2021).

49 Since November 2020, generally five rapidly expanding SARS-CoV-2 lineages  
50 have been discovered and designated as variants of concern (VOCs), *i.e.*, the Alpha,  
51 Beta, Gamma, Delta, and Omicron (Oude Munnink et al. 2021) (**Supplementary**  
52 **Figure 1**). Besides the current Omicron, among these lineages, the Alpha and Delta  
53 VOCs were dominant in frequency over a relatively long period of time. With gradual  
54 resumption of air travel, Customs, and ports, certain previously isolated areas were  
55 riskily exposed to the SARS-CoV-2 variants. These variants, either with higher  
56 infectivity or increased pathogenicity, could trigger multiple outbreak waves unless  
57 they are detected timely and accurately (Tao et al. 2021, Oude Munnink et al. 2021).

58 Although quantitative reverse transcription PCR (RT-qPCR) performs as a gold  
59 standard for the SARS-CoV-2 detection, it is barely used to genotype the  
60 SARS-CoV-2 VOCs due to the limitations as an amplicon-based method. The current  
61 method is heavily based on in-depth whole-genome sequencing, which not only relies  
62 on bulk instruments and trained personnel but is also time-consuming and with  
63 relatively high cost (Crits-Christoph et al. 2021, Kumar et al. 2021). A recent study  
64 showed that the multiplex qPCR could discriminate some SARS-CoV-2 VOCs by  
65 targeting specific small deletions( Vogels et al. 2021). However, this method is  
66 insensitive to the key point mutations and other developing variations in  
67 SARS-CoV-2. Similarly, antigen-based detection assays have lower sensitivity than

68 RT-qPCR and have not yet been reported to identify SARS-CoV-2 VOCs (Peto and  
69 Team 2021).

70 CRISPR-based technology was proven to have unique advantages in molecular  
71 diagnosis over the conventional PCR methods in terms of specificity and operability  
72 (Chen et al. 2018, Joung et al. 2020, Fozouni et al. 2021). Two CRISPR-based  
73 COVID-19 diagnostic methods, DETECTR and SHERLOCK, have been developed  
74 using either Cas12a or Cas13a, with the characteristics of rapid, ultrasensitive and  
75 easy-to-implement (Broughton et al. 2020, Patchesung et al. 2020). Moreover, CRISPR  
76 assays such as RAY were employed to identify the point mutations in SARS-CoV-2  
77 due to the high specificity of Cas/guide-RNA recognition (Kumar et al. 2021, Wang et  
78 al. 2021). Nevertheless, the relying on well-designed ligation probes somehow limited  
79 the targeting capability to diverse mutation sites. Recently, CRISPR-based  
80 point-of-care tests (POCT) of SARS-CoV-2 were reported (de Puig et al. 2021, Teng  
81 et al. 2019). The methods provided visual readout using minimal fluorescent  
82 instruments and could identify multiple SARS-CoV-2 VOCs, among the synthetic  
83 samples though. Hence, significant efforts are still needed in respect to improving the  
84 detection sensitivity and validating the methods with clinical samples.

85 Here, we report a method combining reverse transcription-recombinase  
86 polymerase amplification (RT-RPA) and CRISPR-Cas12a technology based on our  
87 HOLMES test platform (Li, Cheng, Liu, et al. 2018, Li, Cheng, Wang, et al. 2018),  
88 aiming to detect and discriminate SARS-CoV-2 VOCs. By exchanging the crRNA  
89 sequences, the method (RRCd) achieved to discriminate the well-known single  
90 nucleotide polymorphisms (SNPs) of N501Y and T478K as well as the small deletion  
91 of  $\Delta$ H69-V70, corresponding to the major VOCs worldwide. RRCd was validated in  
92 204 clinical samples after being systematic optimization, showing 99% positive

93 predictive agreement and 100% negative predictive agreement, respectively. The  
94 results of RRCd could be visualized within about one hour. Moreover, all procedures  
95 including the sample lysis were able to carry out at 37 °C and with no needs for RNA  
96 extraction and purification, which is very conducive to the development of POCT  
97 products.

98

## 99 **Results**

### 100 **Technical route of RRCd assay**

101 The CRISPR-*LbCas12a*-based nucleic acid test platform HOLMES (Li, Cheng,  
102 Wang, et al. 2018) was chosen as the starting core to design the technical route for  
103 RRCd (**Figure 1, Supplementary Figure 2**). We conduct a two-step RT-RPA  
104 amplification on SARS-CoV-2 genes to provide adequate double-stranded DNA  
105 (dsDNA) for the following CRISPR recognition system (**Figure 1, II**). By designing  
106 specific crRNA, Cas12a recognizes and *cis*-cleaves the dsDNA templates of  
107 SARS-CoV-2 or its variants. Meanwhile, the formation of the ternary complex of  
108 Cas12a-crRNA-dsDNA activates the *trans*-activity of Cas12a, which leads to the  
109 cleavage of the non-targeted single-stranded DNA (ssDNA) probe in the system  
110 (**Figure 1, III**). The results could be quantified directly by fluorescence detection of  
111 the fluorophore-quencher ssDNA (FQ-ssDNA) (**Figure 1, IIIa**) or captured by  
112 lateral-flow strip using the FITC-Biotin ssDNA (FB-ssDNA) (**Figure 1, IIIb**).

113 Hence, different from the previous methods (Broughton et al. 2020, Patchsung  
114 et al. 2020, Ding et al. 2020), RRCd combines the advantages of high sensitivity of  
115 RT-RPA (Lobato and O'Sullivan 2018) and high specificity of CRISPR-Cas12a (Chen  
116 et al. 2018) (**Table 1**). In comparison with Cas9 and Cas13, Cas12a in RRCd

117 possesses greater specificity and lower mismatch tolerance (Chen et al. 2018), making  
118 it more suitable for SARS-CoV-2 VOCs genotyping.

119

## 120 **The specificity analyses of RRCd assay**

121 Representative mutations in spike (S) protein were used for genotyping of the  
122 SARS-CoV-2 lineages (Munnink et al. 2021) (**Figure 2A**). By screening optimal  
123 RT-RPA primers (**Supplementary Figure 3**) and crRNAs (**Supplementary Figure 4**)  
124 that target to the S protein encoding gene, RRCd was readily applied for the detection  
125 and discrimination of SARS-CoV-2 VOCs (**Figure 2B-G**). These VOCs include the  
126 first reported Alpha and Beta mutation N501Y (Tegally et al. 2021) (**Figure 2B, C**),  
127 the recent reported T478K mutation in Delta and Omicron VOCs (Kumar et al. 2022)  
128 (**Figure 2D, E**), and the small deletions such as  $\Delta$ H69-V70 in Alpha and Omicron  
129 VOCs (Meng et al. 2021) (**Figure 2F, G**). The N501Y mutation in the  
130 receptor-binding domain (RBD) of S protein was reported to cause an increased  
131 transmission and infectivity of SARS-CoV-2 (Liu et al. 2022). The T478K mutation in  
132 the RBD is also involved in higher transmissibility by the increased affinity to human  
133 ACE2 receptor (Kumar et al. 2022), while the deletion of H69V70 at the N-terminal  
134 domain is shown to allow the virus to replicate more efficiently (Meng et al. 2021).

135 Our test results were demonstrated by both the fluorescence-based and  
136 lateral-flow readouts, representing the *trans*-cleavage activity of Cas12a (Chen et al.  
137 2018, Li, Cheng, Liu, et al. 2018) (**Figure 2B-G**). Additionally, we confirmed this  
138 specific cleavage using polyacrylamide gel electrophoresis analyses by leveraging of  
139 the Cas12a *cis*-cleavage activity (Chen et al. 2018) (**Figure 2H-J**). Moreover, RRCd  
140 can be used for the discrimination of SARS-CoV-2 from other phylogenetic related  
141 viruses (**Supplementary Figure 5**).

142

### 143 **The detection limit of RRCd**

144 To determine the limit of detection (LoD) of RRCd, we built a standard curve to  
145 dissect the correspondences between the viral copy numbers and the  $C_t$  values using  
146 SARS-CoV-2 pseudovirus (**Supplementary Figure 6**). The  $C_t$  values of each dilution  
147 were measured using RT-qPCR targeting *N* gene or *ORF1ab* gene to mimic the  
148 clinical  $C_t$  ranges. Despite showing distinct kinetics, the fluorescence-based readouts  
149 revealed that the LoDs of all the targeted regions (*E* gene, N501, Y501, T478, and  
150 K478 of *S* gene) were ~10 copies per reactions, corresponding to a  $C_t$  value of 35 in  
151 the RT-qPCR assay (**Figure 3**). The fluorescence results from a 30-min CRISPR  
152 reaction suggested that the detection sensitivity of N501 is a slightly higher than that  
153 of Y501 (**Figure 3B, C**), while the detection sensitivity of T478 is a slightly lower  
154 than that of K478 (**Figure 3D, E**). It is worth noting that the detection sensitivity of  
155 the lateral-flow readouts is about 10-folds lower than that of the fluorescence-based  
156 readouts (**Figure 3**). The detection of Y501 and K478 was shown to be the most  
157 sensitive when using the lateral-flow readout, with the LoDs of ~10 copies per  
158 reactions (**Figure 3C, E**).

159 To avoid false-discriminative results, we further assessed the factors that may  
160 affect the detection sensitivity in RRCd, including the sample volume and probe  
161 inputs, the usage of RNase H, T4 gene 32 protein, Bsu DNA polymerase, RPA kits,  
162 and  $Mg^{2+}$ . We found the sample volume and the usage of T4 gene 32 protein (Villalva  
163 et al. 2001) are the key factors affecting RRCd sensitivity mostly (**Supplementary**  
164 **Figure 7**).

165

166

## 167 **Validation of RRCd in detection and discrimination of clinical samples**

168       Based on the optimized procedures, we evaluated the performance of RRCd on  
169 detecting COVID-19 clinical samples isolated from nasopharyngeal and salivary  
170 swabs. In coordination with the scenario of POCT, our available samples were  
171 collected from Shanghai Customs where the susceptible patients were characterized as  
172 asymptomatic and with low virus load (**Supplementary Figure 8**). To minimize the  
173 cognitive bias, all information of the clinical samples was confidential to study staff  
174 before the detection.

175       A validation study of SARS-CoV-2 detection was conducted on a total of 96  
176 clinical samples (54 RT-qPCR-verified positive samples and 42 RT-qPCR-verified  
177 negative samples). Both *E* gene and *S* gene were used as the targeted sequences to  
178 acquire the double-checked detection results (**Figure 4, Supplementary Figure 9**).  
179 RRCd identified all the positive samples with  $C_t < 33$  through both lateral-flow and  
180 fluorescence-based readouts. In addition, 42 COVID-19 negative samples were all  
181 identified without false positive results from both readouts. Samples beyond the  $C_t$   
182 value of 32 were more likely to be detected by targeting the *E* gene ( $C_t \leq 35$ , 100%  
183 detected) than the *S* gene (**Figure 4**). The detection sensitivity of these results was  
184 comparable to the RT-LAMP-Cas12 based DETECTR (Broughton et al. 2020) and  
185 the RT-RPA-Cas13 based SHERLOCK (Patchesung et al. 2020), showing a 99%  
186 positive predictive agreement (PPA) and 100% negative predictive agreement (NPA)  
187 in both readouts ( $C_t < 33$ ) (**Table 2**).

188       We next evaluated the performance of RRCd on discrimination of SARS-CoV-2  
189 VOCs. The 501 position of *S* gene was used as a target to detect SARS-CoV-2 VOCs,  
190 such as the Alpha, Beta, Gamma, and Omicron (Tegally et al. 2021). A total of 68  
191 clinical samples, consisting of 28 genome-sequencing-verified N501 samples and 19



192 genome-sequencing-verified Y501 samples, were collected from March 3<sup>rd</sup> to April  
193 10<sup>th</sup> 2021 at Shanghai Customs. RRCd discriminated all the variants from samples  
194 with a  $C_t < 32$ , either using lateral-flow readouts or fluorescence-based readouts  
195 (**Figure 5A, Supplementary Figure 10**). However, the discrimination ability  
196 decreased strikingly when testing the samples with  $C_t$  values beyond 33, which is  
197 possibly due to the relatively high LoD of *S* gene 501 as mentioned above (**Figure 3**).

198 The 478 position of *S* gene could be used as a target to identify Delta and  
199 Omicron VOCs (**Figure 5B, Supplementary Figure 11**). A total of 40 clinical  
200 positive samples, consisting of 7 genome-sequencing-verified T478 samples and 14  
201 genome-sequencing-verified K478 samples, were collected from May 27<sup>th</sup> and  
202 October 29<sup>th</sup> 2021. RRCd was able to discriminate all the variants targeting the *S* gene  
203 478. Moreover, RRCd displayed a relatively higher sensitivity in detecting the  
204 position of 478 than that of 501, with the  $C_t$  value reaching 34. Although using a  
205 relatively small sample group, the detection results were confirmed by both readouts  
206 with 0% false-discriminant rates (**Figure 5B**). Taken together, these clinical data  
207 suggested that RRCd was able to detect and discriminate the SARS-CoV-2 VOCs,  
208 accurately and sensitively (**Table 2**).

209

## 210 Discussion

211 Although a decreased lethality of the circulating Omicron has been reported, its  
212 overall mortality rate has not dropped because its dramatically increased infectivity  
213 (Nyberg et al. 2022). The frequent outbreak waves of COVID-19 highlight the needs  
214 for detection methods that are rapid, sensitive, and specific. However, the current  
215 method relying on deep genome sequencing is limited by the high cost, long  
216 turn-around time, and the reduced overall sensitivity (Kumar et al. 2021). Although

217 the recently developed CRISPR-based methods were characterized as sensitive and  
218 easy-to-implement, most of them were barely validated by the large clinical samples  
219 or have a limited adaptability (Wang et al. 2021, Teng et al. 2019, de Puig et al. 2021).

220 In the present study, RRCd completed in ~1 hour and displayed a sensitivity  
221 down to 10 copies per reaction. By targeting and identifying the representative N501Y,  
222 T478K and  $\Delta$ H69-V70 mutations, RRCd discriminated COVID-19 samples of Alpha,  
223 Delta, and Omicron VOCs. The method was validated in 204 clinical COVID-19  
224 samples, with 99% PPA and 100% NPA for the samples of  $C_t < 33$  through both the  
225 fluorescence and the lateral-flow readouts (**Table 2**). Moreover, The SARS-CoV-2  
226 detection by direct lysing the clinic samples without RNA extraction and purification  
227 was demonstrated (**Supplementary Figure 12**). Although a relatively small sample  
228 size was used, these results indicated that the whole process of RRCd including the  
229 RT-RPA amplification and the lateral-flow detection is independent of electrical  
230 devices, which may facilitate the development of POCT products (**Table 1**).

231 In addition, the RRCd assay has the potential to be easily adapted to detect  
232 novel mutations on SARS-CoV-2 or other viruses by designing the new RT-RPA  
233 primers and crRNAs, without changing the subsequent detection procedures and  
234 ssDNA probes (**Figure 1, Supplementary Figure 2**). Overall, RRCd can be  
235 performed in sites with few detection equipment (*e.g.*, self-testing) or limited power  
236 access (*e.g.*, underdeveloped areas), or situations when quick turnaround times are  
237 needed (*e.g.*, hospital emergency). Nevertheless, the POCT products for RRCd needs  
238 to be further investigated.

239

## 240 **Materials and methods**

### 241 **Clinical sample collection and ethics statement**

242 All 204 nasopharyngeal and salivary samples were collected at Shanghai  
243 International Travel Healthcare Center (SITHC), Shanghai Customs District P. R.  
244 China, from March 3<sup>rd</sup> and to October 29<sup>th</sup> 2021. The samples were treated in strict  
245 accordance with WHO recommended standard operation procedure. Ethical approval  
246 of the study was given by the Bioethics Committee of Bio-X Institute of Shanghai  
247 Jiao Tong University (COA: M202007).

248

### 249 **RT-qPCR for the SARS-CoV-2 detection**

250 The viral RNA of each swab was extracted and purified from a 200 µl-swab  
251 transport media using an automatic nucleic acid platform (SSNP-3000A,  
252 Bioperfectus tech., China) according to the manufacturer's instruction. A 100 µl  
253 RNase-free water was used to elute the RNA. Viral lysis and RNA extraction were  
254 performed in a biosafety level 3 laboratory, whereas other procedures were  
255 performed in a biosafety level 2 laboratory.

256 The quantitative reverse transcription PCR (RT-qPCR) for SARS-CoV-2  
257 detection was performed with a 2019-nCoV nucleic acid detection kit (BioGerm,  
258 Shanghai, China) according to the manufacturer's protocol. Each RT-qPCR reaction  
259 had a final volume of 25 µl, including 5 µl purified RNA, 12 µl reaction buffer, 4 µl  
260 enzyme solution and 4 µl probe primers solution. RT-qPCR assay was performed on  
261 QuantStudio Dx Real-Time PCR (Applied Biosystems, MA, USA) under the  
262 following conditions: incubation at 50 °C for 15 min and 95 °C for 5 min, 45 cycles  
263 of denaturation at 94 °C for 15 s, and extension and fluorescence signal reading at  
264 55 °C for 45 s. Two target genes, *i.e.*, the *ORF1ab* gene and the *N* gene, were

265 simultaneously amplified and tested in the RT-qPCR assay. The test result was  
266 deemed as positive when the cycle threshold values ( $C_t$  value) of both  
267 *ORF1ab* and *N* genes  $\leq 38$ ; otherwise, a negative result was deemed. These  
268 diagnostic criteria were based on the recommendation from the National Institute for  
269 Viral Disease Control and Prevention (China)  
270 ([http://ivdc.chinacdc.cn/kyjz/202001/t20200121\\_211337.html](http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html)).

271

### 272 **Design and screening of the RT-RPA primers and crRNAs**

273 For the detection of SARS-CoV-2, *E* gene was selected as the test target using  
274 the RT-RPA primers and crRNA recommended by WHO with minor modifications  
275 (**Supplementary Table 1**).

276 For the detection of SARS-CoV-2 VOCs, the representative mutations in the *S*  
277 gene were selected as the test targets. Aiming to distinguish the most prevailing  
278 SARS-CoV-2 VOCs (*i.e.*, the Alpha, Delta, and Omicron), we designed the RT-RPA  
279 primers on the conserved regions flanking the mutations of *S* gene 478 and 501  
280 (**Supplementary Table 1**), respectively, and screened the best pairs by agarose gel  
281 analyses for the amplification efficiency of dsDNA. Two pairs of optimal RT-RPA  
282 primers (S501RPAF1/S501RPAR1 and S478RPAF3/S478RPAR5) were selected for  
283 the detection of *S* gene 478 and 501, respectively. To further evaluate their  
284 applicability in the detection of clinical samples, these RT-RPA primers were aligned  
285 with 859,132 full-length SARS-CoV-2 genome sequences collected from January 1<sup>st</sup>  
286 2021 to December 31<sup>th</sup> 2021 in the GISAID database (Buch et al. 2011). The results  
287 showed that these pairs of RT-RPA primers hit 99.7% of the genome sequences,  
288 demonstrating a good applicability in detection of prevailing clinical samples.

289 Optimal crRNAs for the discrimination of *S* gene 501 variants were assessed

290 by determining the specificity of the crRNA to the single-base mismatched *S* gene  
291 templates. DNA fragments containing wild-type *S* gene 501 with point mutations  
292 were synthesized in pUC19 backbone plasmid by Sangon Biotech. These *S* gene 501  
293 regions were transcribed into RNA using HiScribe T7 High Yield RNA Synthesis kit  
294 (Cat# E2050S, New England Biolabs) at 37 °C for 4 h, whose products were further  
295 analyzed using both fluorescence-based and lateral-flow readouts. The crRNA-N501  
296 was employed to discriminate the single-base mismatches. Based on this approach,  
297 we designed the crRNAs for the discrimination of other SARS-CoV-2 VOCs. All  
298 crRNA and RT-RPA primer sequences used in this study are listed in  
299 **Supplementary Table 1.**

300

### 301 **crRNA generation**

302 The DNA templates (**Supplementary Table 1**) for *in vitro* transcription (IVT)  
303 of crRNAs were designed with T7 primer binding sites using CRISPR-RT Design  
304 Tool (<http://bioinfolab.miamioh.edu/CRISPR-RT>) and synthesized by Sangon  
305 Biotech (Shanghai, China). The crRNAs were transcribed using HiScribe T7 High  
306 Yield RNA Synthesis kit (Cat# E2050S, New England Biolabs) at 37 °C for 16 h.  
307 Then, the crRNAs were purified using RNA Clean and Concentrator kit (Cat# R1017,  
308 Zymo Research). The concentration of crRNA was quantified by NanoDrop 2000C  
309 spectrophotometer (Thermo Scientific) and stored at -80 °C before use.

### 310 **Reverse transcription and recombinase polymerase amplification (RT-RPA)**

311 A 20 µl volume-basic RT reaction mixture was used with 1 × RT buffer (Cat#  
312 EP0442, Thermo Scientific), 10 µl RNA template, 200 U RevertAid reverse  
313 transcriptase (Cat# EP0442, Thermo Scientific), 1.25 µM RT-RPA forward and

314 reverse primer mix, 1 mM dNTP mix (Cat# P031-01, Vazyme, Nanjing, China), and  
315 20 U RNase inhibitor (Cat# N8080119, Thermo Scientific). The RT reaction mixture  
316 was incubated at 37 °C for 15 min to generate cDNA. Then, a 10 µl RT product was  
317 transferred into the 50 µl-basic RPA reaction mixture, which contains 29.5 µl  
318 rehydration buffer, one freeze-dried RPA reaction pellet (Cat# TABAS03KIT,  
319 TwistDx), 0.5 µM RT-RPA forward and reverse primer mix, and 14 mM MgOAc  
320 (last added to initiate the reaction). The RPA reaction mixture was incubated at 37 °C  
321 for another 15 min. The RNA extracts from SARS-CoV-2 pseudovirus and the  
322 RNase-free water were used as the positive control (PC) and negative control (NC),  
323 respectively.

324

### 325 **CRISPR *trans*-cleavage assay for fluorescence-based and lateral-flow readouts**

326 Briefly, a 100 µl volume basic CRISPR reaction mixture was used with 1 ×  
327 *Lba*Cas12a buffer, 5 µl RT-RPA product, 0.2 µM *Lba*Cas12a (Cat# M0653T, New  
328 England Biolabs), 0.6 µM crRNA, 10 µM MgCl<sub>2</sub>, 10 nM fluorophore  
329 (FAM)-quencher (BHQ1) ssDNA probe (FQ-ssDNA, Sangon Biotech) for the  
330 fluorescence-based detection, or 50 nM FTIC-Biotin ssDNA probe (FB-ssDNA,  
331 Zoonbio Biotechnology, Nanjing, China) for the lateral flow-based detection.

332 For the fluorescence-based readout, a 96-well plate containing 100 µl reaction  
333 mixture was incubated at 37 °C using the Cytation 5 Mul-Mode Reader (BioTek, VT,  
334 USA). Usually, a 60-min monitoring was used with an interval time of 30 s. The  
335 fluorescence excitation and emission wavelength were set as 485 nm and 520 nm,  
336 respectively. The relative fluorescence intensity ( $F/F_0$ ) was calculated as the  
337 fluorescence signal relative to the starting signal. Generally, the fluorescence signals  
338 at the 30 min-reactions were quantified as  $F_{30}/F_0$ . In this study,  $(F_{30}/F_0)_{\text{Sample}} /$

339  $(F_{30}/F_0)_{NC} \geq 1.2$  indicates the positive result while  $(F_{30}/F_0)_{Sample} / (F_{30}/F_0)_{NC} < 1.2$   
340 indicates the negative result.

341 For the lateral flow readout, a 100  $\mu$ l-reaction mixture was incubated in an  
342 Eppendorf tube at 37 °C for 30 min. Then, the HybriDetect strip (Milenia Biotec,  
343 Giessen, Germany) was placed into the Eppendorf tube, and the C-line and/or T-line  
344 were visualized and stabilized in ~2 min. The relative greyness of the T-line (G) was  
345 quantified using ImageJ. In this study,  $G_{Sample} / G_{NC} \geq 1.5$  indicates the positive result  
346 while  $G_{Sample} / G_{NC} < 1.5$  indicates the negative result. Due to the incomplete  
347 digestion of FB-ssDNA, some positive test results displayed two lines (T-line and  
348 C-line) on the strips.

349

### 350 **CRISPR *cis*-cleavage assay**

351 Upon detection of the targeted sites, the CRISPR-Cas12a system is capable to  
352 *cis*-cleave the dsDNA template into two short fragments, the activity of which was  
353 determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
354 (SDS-PAGE). After a 30-min incubation of the CRISPR reaction mixture as  
355 described above, the mixture was denatured at 95 °C for 5 min. Then, it was loaded  
356 into an 8% SDS-PAGE for 45 min at 150 V. The gel was stained with GelRed  
357 (Biotium, CA, USA) and analyzed by Image J.

358

### 359 **Specificity of RRCd assay**

360 To test if RRCd could discriminate SARS-CoV-2 from the phylogenetically  
361 related viruses, DNA fragments containing selected regions of *N* gene of SARS-CoV  
362 (NC\_004718.3), MERS CoV (NC\_019843.3), and H1N1 (NC\_026433.1,  
363 NC\_026434.1) were synthesized from Sangon Biotech (**Supplementary Table 2**),

364 and then cloned into a T7 promoter expression plasmid to be used as the templates for  
365 IVT of viral RNAs, respectively. The transcribed RNAs were detected using  
366 crRNA-SARS-CoV2 *N* by the RRCd assay as described above.

367

368 **Building a standard curve to determine the relationship between viral copy**  
369 **numbers and the  $C_t$  values**

370 The pseudovirus SARS-CoV-2 ab II EMNS S-MT and  
371 SARS-CoV-2-MT-B.1.617.2. (**Supplementary Table 3**) were purchased from  
372 FUBIO, Nanjing, China. To establish the correlation between viral copy numbers  
373 and the  $C_t$  values of SARS-CoV-2, we built a standard curve using a gradient  
374 dilution ( $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$ ,  $1 \times 10^2$ , 10 and 5 RNA copies per reaction) of  
375 SARS-CoV-2 ab II EMNS S-MT. The  $C_t$  values of the samples were determined by  
376 targeting *N* gene and *ORF1ab* gene with RT-qPCR as mentioned above. Results were  
377 plotted against the viral copy numbers yielding a linear relationship.

378

379 **Limit of detection (LoD) of RRCd assay**

380 To determinate the detection limits of RRCd assay for different SARS-CoV-2  
381 variants (*E* gene, T478, K478, N501 and Y501 in *S* gene), nine serial dilutions ( $1 \times$   
382  $10^7$ ,  $1 \times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$ ,  $1 \times 10^2$ , 10 and 5 copies per reaction) of  
383 SARS-CoV-2 pseudovirus RNAs were used and their fluorescence-based and  
384 lateral-flow readouts were analyzed as described above. For the dilutions ( $1 \times 10^7$ ,  $1$   
385  $\times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$  and  $1 \times 10^2$  copies per reaction), at least three  
386 independent experiments were performed, while for the dilutions with 10 and 5  
387 copies per reaction, at least five independent experiments were conducted.  
388 RNase-free water was used as the negative control.



389

### 390 **Whole-genome sequencing of clinical samples**

391 To determine the lineages of the RT-qPCR-verified positive clinical samples,  
392 whole-genome sequencing of SARS-CoV-2 cDNA was conducted by Illumina  
393 Next-generation sequencing. The first-strand cDNA of SARS-CoV-2 RNA was  
394 generated using the SuperScript IV First-Strand Synthesis System (Cat# 18091050,  
395 Thermo Fisher Scientific). The corresponding libraries were constructed using the  
396 cDNAs with the ARTIC SARS-CoV-2 amplification protocol (as described in  
397 <https://artic.network/ncov-2019>). Paired-end 150 bp sequencing was performed for  
398 each library on Illumina X-10. Genome assembly was done using CLC Genomics  
399 Workbench (<http://www.clcbio.com/products/clcgenomics-workbench/>) (Liu and Di  
400 2020). The Phylogenetic Assignment of Named Global Outbreak Lineages  
401 (PANGOLIN) (<https://virological.org/t/pangolin-web-application-release/482>) (Lam  
402 et al. 2020) and the NextClade (<https://clades.nextstrain.org/>) (Hadfield et al. 2018)  
403 were used for lineage classification and clade classification, respectively. All the S  
404 gene from the positive clinical samples used in this study were re-sequenced by  
405 Sanger method.

406

### 407 **Optimization of RRCd assay**

408 To optimize the RT reaction, we first investigated the effects of different RNA  
409 input (1, 5, or 10  $\mu$ l) on the detection sensitivity of RRCd. RNA was extracted from  
410 a positive clinical sample ( $C_t = 30$ ) as described above and the SARS-CoV-2 *E* gene  
411 was used as the test target.

412 RNase H is an endoribonuclease that specifically hydrolyzes the RNA-DNA  
413 hybrids(Qian et al. 2020), while T4 gene 32 protein is known to increase the

414 efficiency of reverse transcriptase(Villalva et al. 2001) and Bsu DNA polymerase has  
415 the strand displacement DNA synthesis activity(Piepenburg et al. 2006). To evaluate  
416 the effects of these enzymes on RT-RPA efficiency, a basic RT reaction mixture was  
417 prepared as described above with or without the addition of 250 U RNase H (Cat#  
418 M0297S, New England Biolabs), 16.5  $\mu$ M T4 gene 32 protein (Cat# M0300L, New  
419 England Biolabs) or 0.25 U Bsu DNA polymerase (Cat# M0330S, New England  
420 Biolabs), respectively.

421 The corresponding RT products were used as inputs to the RPA assay and  
422 subsequent products were analyzed by fluorescence based CRISPR assay as  
423 described above. Finally, a 20  $\mu$ l volume-optimized RT reaction mixture was  
424 obtained as below: 1  $\times$  RT buffer, 10  $\mu$ l template RNA, 200 U RevertAid reverse  
425 transcriptase (Thermo Scientific), 1.25  $\mu$ M RT-RPA forward and reverse primer mix,  
426 1 mM dNTP mix, 20 U RNase inhibitor (Thermo Scientific), 250 U RNase H (New  
427 England Biolabs) and 16.5  $\mu$ M T4 gene 32 protein (New England Biolabs).

428 For screening of an optimal RPA kit, four RPA assay kits were compared under  
429 the same conditions, including Amp-Qitian kit (Qitian gene Biotech, Wuxi, China),  
430 Amp-Future kit (Amp-Future, Weifang, China), TwistAmp Baic kit (TwistDx,  
431 Cambridge, UK), and Amp-Yizhi Kit (Yizhi Biotech, Shenzhen, China). Briefly, 10  
432  $\mu$ l RT product was transferred into a 50  $\mu$ l volume basic RPA reaction mixture using  
433 these four kits, respectively, which contains 29.5  $\mu$ l rehydration buffer, one  
434 freeze-dried RPA reaction pellet, 0.5  $\mu$ M RT-RPA forward and reverse primer mix,  
435 and 14 mM MgOAc (last added to initiate the reaction). The RPA reaction mixture  
436 was incubated at 37  $^{\circ}$ C for 15 min. RNase-free water was used as the negative  
437 control.

438 To investigate the possible effects of T4 gene 32 protein and Bsu DNA

439 polymerase on RPA reaction, basic RPA reaction mixture was prepared as described  
440 above with or without the addition of 16.5  $\mu\text{M}$  T4 gene 32 protein (Cat# M0300L,  
441 New England Biolabs) or 0.25U Bsu DNA polymerase (Cat# M0330S, New England  
442 Biolabs).

443 The RT-RPA products were analyzed by fluorescence based CRISPR assay as  
444 described above. Finally, a 50  $\mu\text{l}$  volume-optimized RPA reaction mixture was  
445 obtained as below: 29.5  $\mu\text{l}$  rehydration buffer (TwistDx), one freeze-dried RPA  
446 reaction pellet (TwistDx), 10  $\mu\text{l}$  RT product, 0.5  $\mu\text{M}$  RT-RPA forward and reverse  
447 primer mix, 16.5  $\mu\text{M}$  T4 gene 32 protein (Cat# M0300L, New England Biolabs) and  
448 14 mM MgOAc.

449 To determine if the CRISPR reaction has a higher efficiency using manganese  
450 rather than magnesium, as described before (Li et al. 2020). The fluorescence-based  
451 CRISPR assay was used to quantify the results as described above, with 10 mM  
452  $\text{MnCl}_2$  or  $\text{MgCl}_2$  in the basic CRISPR reaction mixture.

453 Furthermore, the optimal concentrations of FQ-ssDNA and FB-ssDNA probes  
454 were determined within the basic CRISPR reaction mixture. The FQ-ssDNA probe  
455 (10, 15, or 20 nM) and FB-ssDNA probe (0.5, 5, 25, 50, 125, 200, 500, 1000, or  
456 2000 nM) were used in the CRISPR reaction, and the corresponding reaction  
457 fluorescence intensities and lateral-flow readouts were recorded as described above,  
458 respectively.

459 Finally, a 100  $\mu\text{l}$  volume-optimized CRISPR reaction mixture was obtained as  
460 below: 1  $\times$  *LbaCas12a* buffer (Cat# M0653T, New England Biolabs), 5  $\mu\text{l}$  RT-RPA  
461 product, 0.2  $\mu\text{M}$  *LbaCas12a* (Cat# M0653T, New England Biolabs), 0.6  $\mu\text{M}$  crRNA,  
462 10  $\mu\text{M}$   $\text{MgCl}_2$ , and 20 nM FAM-BHQ1 ssDNA probe for the fluorescence-based  
463 detection, or 200 nM FTIC-Biotin ssDNA probe for the lateral flow-based detection.

464

## 465 **Comparison of the one-step and two-step RT-RPA**

466       The amplification efficiency from the one-step and two-step RT-RPA was  
467 compared by using *E* gene as the detection target. The two-step RT-RPA was  
468 conducted using the optimized RT-RPA mixtures as described above, while the  
469 one-step RT-RPA was performed by adding all the reaction reagents at once and  
470 incubated at 37 °C for 30 min. The 50 µl-reaction mixture of the one-step RT-RPA  
471 contains 29.5 µl rehydration buffer, 10 µl RNA template, one freeze-dried Twist RPA  
472 reaction pellet, 2.5 µM RT-RPA forward and reverse primer mix, 0.4 mM dNTP mix,  
473 200 U RevertAid reverse transcriptase, 6.6 µM T4 gene 32 protein, 100 U RNase H,  
474 10 U RNase inhibitor, and 14 mM MgOAc. The RT-RPA products were loaded into  
475 8% PAGE gel and the relative greyness of sample bands was quantified using  
476 ImageJ.

477

## 478 **Validation of RRCd in detection and discrimination of clinical samples**

479       To evaluate the performance of RRCd on SARS-CoV-2 clinical samples, a  
480 total of 204 swabs were collected at SITHC from March 3<sup>rd</sup> and to October 29<sup>th</sup> 2021  
481 and were used to perform the RRCd assay. Both lateral-flow and fluorescence-based  
482 readouts were recorded. A total of 96 clinical samples were used to detect  
483 SARS-CoV-2 by targeting *E* gene and *S* gene, and a total of 108 clinical samples  
484 were used to detect and discriminate the SARS-CoV-2 VOCs by targeting *S* gene  
485 501 or 478. The RRCd results were analyzed and compared with the results of  
486 RT-qPCR and genome sequencing.

487

## 488 **RRCd using the directly released RNA**

489 Viral RNAs from SARS-CoV-2 pseudovirus and clinical samples were  
490 released directly by a Sample release reagent kit (Sansure Biotech, Changsha, China)  
491 according to the manufacturer's instructions with minor modifications. The swab  
492 storage solution and the sample release reagent were mixed in a ratio of 1:1 and  
493 incubated at 37 °C for 5 min before subsequent assays.

494

#### 495 **Statistical analysis**

496 Data were represented as mean  $\pm$  S.D. from three independent experiments  
497 otherwise indicated. Statistical significances were analyzed by using the R (version  
498 4.1.1). Unpaired one-tailed *t*-test was applied to investigate the differences between  
499 groups assuming *P* value  $< 0.05$  as significant.

500

#### 501 **Acknowledgements**

502 We are grateful to Prof. Xian-En Zhang for generously providing the  
503 pseudovirus, and Prof. Hang Dai and Dr. Xiaonan Yang for constructive discussion on  
504 this project. This study was supported by the National Key R&D Program of China  
505 (2019YFA0904003, 2020YFA0909100), the Strategic Priority Research Program of  
506 the Chinese Academy of Sciences, China (XDB38020300), the Guangdong Basic and  
507 Applied Basic Research Foundation (2021A1515012511), and the General  
508 Administration of Customs Project (2020HK003).

509

#### 510 **Author contributions**

511 G.P.Z., Z.G.T. and W.Z. conceived and designed the study. G.T., Z.Z., W.T.  
512 and F.L. performed the experiments and analyzed data. All authors contributed to  
513 writing and editing of the manuscript. W.Z. supervised the research.

514

## 515 **Competing interests**

516 G.Y.T., W.T., G.P.Z. and W.Z. are co-inventors on patent applications filed by  
517 Shenzhen Institutes of Advanced Technology relating to the work in this manuscript.  
518 The remaining authors declare no conflict of interest.

519

## 520 **References**

521

- 522 Broughton, J. P., X. Deng, G. Yu, C. L. Fasching, V. Servellita, J. Singh, X. Miao, J. A. Streithorst, A.  
523 Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E. Hsu, W. Gu, S. Miller, C. Y. Pan,  
524 H. Guevara, D. A. Wadford, J. S. Chen, and C. Y. Chiu. 2020. "CRISPR-Cas12-based  
525 detection of SARS-CoV-2." *Nat Biotechnol* 38 (7):870-874. doi:  
526 10.1038/s41587-020-0513-4.
- 527 Buch, J., K. Roomp, G. Bach, L. Steinbruck, M. Beer, V. Gregory, N. Komadina, Y. Lan, I. Monne, C.  
528 Smith, S. Fujisaki, P. Bogner, and T. Lengauer. 2011. "GISAID - a global initiative on  
529 sharing all influenza data." *Influenza and Other Respiratory Viruses* 5:419-419.
- 530 Chen, J. S., E. Ma, L. B. Harrington, M. Da Costa, X. Tian, J. M. Palefsky, and J. A. Doudna. 2018.  
531 "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity."  
532 *Science* 360 (6387):436-439. doi: 10.1126/science.aar6245.
- 533 Crits-Christoph, A., R. S. Kantor, M. R. Olm, O. N. Whitney, B. Al-Shayeb, Y. C. Lou, A. Flamholz,  
534 L. C. Kennedy, H. Greenwald, A. Hinkle, J. Hetzel, S. Spitzer, J. Koble, A. Tan, F. Hyde, G.  
535 Schroth, S. Kuersten, J. F. Banfield, and K. L. Nelson. 2021. "Genome Sequencing of  
536 Sewage Detects Regionally Prevalent SARS-CoV-2 Variants." *Mbio* 12 (1). doi: ARTN  
537 e02703-2010.1128/mBio.02703-20.
- 538 de Puig, H., R. A. Lee, D. Najjar, X. Tan, L. R. Soeknsen, N. M. Angenent-Mari, N. M. Donghia, N. E.  
539 Weckman, A. Ory, C. F. Ng, P. Q. Nguyen, A. S. Mao, T. C. Ferrante, G. Lansberry, H.  
540 Sallum, J. Niemi, and J. J. Collins. 2021. "Minimally instrumented SHERLOCK  
541 (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging  
542 variants." *Sci Adv* 7 (32). doi: 10.1126/sciadv.abh2944.
- 543 Ding, X., K. Yin, Z. Li, R. V. Lalla, E. Ballesteros, M. M. Sfeir, and C. Liu. 2020. "Ultrasensitive and  
544 visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay." *Nat*  
545 *Commun* 11 (1):4711. doi: 10.1038/s41467-020-18575-6.
- 546 Fozouni, P., S. Son, M. Diaz de Leon Derby, G. J. Knott, C. N. Gray, M. V. D'Ambrosio, C. Zhao, N.  
547 A. Switz, G. R. Kumar, S. I. Stephens, D. Boehm, C. L. Tsou, J. Shu, A. Bhuiya, M.  
548 Armstrong, A. R. Harris, P. Y. Chen, J. M. Osterloh, A. Meyer-Franke, B. Joehnk, K. Walcott,  
549 A. Sil, C. Langelier, K. S. Pollard, E. D. Crawford, A. S. Puschnik, M. Phelps, A. Kistler, J.  
550 L. DeRisi, J. A. Doudna, D. A. Fletcher, and M. Ott. 2021. "Amplification-free detection of  
551 SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy." *Cell* 184 (2):323-333  
552 e9. doi: 10.1016/j.cell.2020.12.001.
- 553 Hadfield, J., C. Megill, S. M. Bell, J. Huddleston, B. Potter, C. Callender, P. Sagulenko, T. Bedford,

- 554 and R. A. Neher. 2018. "Nextstrain: real-time tracking of pathogen evolution."  
555 *Bioinformatics* 34 (23):4121-4123. doi: 10.1093/bioinformatics/bty407.
- 556 Joung, J., A. Ladha, M. Saito, N. G. Kim, A. E. Woolley, M. Segel, R. P. J. Barretto, A. Ranu, R. K.  
557 Macrae, G. Faure, E. I. Ioannidi, R. N. Krajeski, R. Bruneau, M. W. Huang, X. G. Yu, J. Z.  
558 Li, B. D. Walker, D. T. Hung, A. L. Greninger, K. R. Jerome, J. S. Gootenberg, O. O.  
559 Abudayyeh, and F. Zhang. 2020. "Detection of SARS-CoV-2 with SHERLOCK One-Pot  
560 Testing." *N Engl J Med* 383 (15):1492-1494. doi: 10.1056/NEJMc2026172.
- 561 Julia L. Mullen, Ginger Tsueng, Alaa Abdel Latif, Manar Alkuzweny, Marco Cano, Emily Haag, Jerry  
562 Zhou, Mark Zeller, Emory Hufbauer, Nate Matteson, Kristian G. Andersen, Chunlei Wu,  
563 Andrew I. Su, Karthik Gangavarapu, Laura D. Hughes and Center for Viral Systems Biology.  
564 2021. Outbreak.info. <https://outbreak.info/situation-reports>."
- 565 Kumar, M., S. Gulati, A. H. Ansari, R. Phutela, S. Acharya, M. Azhar, J. Murthy, P. Kathpalia, A.  
566 Kankan, R. Maurya, J. S. Vasudevan, A. S, R. Pandey, S. Maiti, and D. Chakraborty. 2021.  
567 "FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2  
568 variants on a paper strip." *Elife* 10. doi: 10.7554/eLife.67130.
- 569 Kumar, S., T. S. Thambiraja, K. Karuppanan, and G. Subramaniam. 2022. "Omicron and Delta variant  
570 of SARS-CoV-2: A comparative computational study of spike protein." *J Med Virol* 94  
571 (4):1641-1649. doi: 10.1002/jmv.27526.
- 572 Lam, T. T., N. Jia, Y. W. Zhang, M. H. Shum, J. F. Jiang, H. C. Zhu, Y. G. Tong, Y. X. Shi, X. B. Ni, Y.  
573 S. Liao, W. J. Li, B. G. Jiang, W. Wei, T. T. Yuan, K. Zheng, X. M. Cui, J. Li, G. Q. Pei, X.  
574 Qiang, W. Y. Cheung, L. F. Li, F. F. Sun, S. Qin, J. C. Huang, G. M. Leung, E. C. Holmes, Y.  
575 L. Hu, Y. Guan, and W. C. Cao. 2020. "Identifying SARS-CoV-2-related coronaviruses in  
576 Malayan pangolins." *Nature* 583 (7815):282-285. doi: 10.1038/s41586-020-2169-0.
- 577 Li, B., J. Yan, Y. Zhang, W. Li, C. Zeng, W. Zhao, X. Hou, C. Zhang, and Y. Dong. 2020.  
578 "CRISPR-Cas12a Possesses Unconventional DNase Activity that Can Be Inactivated by  
579 Synthetic Oligonucleotides." *Mol Ther Nucleic Acids* 19:1043-1052. doi:  
580 10.1016/j.omtn.2019.12.038.
- 581 Li, S. Y., Q. X. Cheng, J. K. Liu, X. Q. Nie, G. P. Zhao, and J. Wang. 2018. "CRISPR-Cas12a has  
582 both cis- and trans-cleavage activities on single-stranded DNA." *Cell Res* 28 (4):491-493.  
583 doi: 10.1038/s41422-018-0022-x.
- 584 Li, S. Y., Q. X. Cheng, J. M. Wang, X. Y. Li, Z. L. Zhang, S. Gao, R. B. Cao, G. P. Zhao, and J. Wang.  
585 2018. "CRISPR-Cas12a-assisted nucleic acid detection." *Cell Discov* 4:20. doi:  
586 10.1038/s41421-018-0028-z.
- 587 Liu, C. H., and Y. P. Di. 2020. "Analysis of RNA Sequencing Data Using CLC Genomics  
588 Workbench." *Methods Mol Biol* 2102:61-113. doi: 10.1007/978-1-0716-0223-2\_4.
- 589 Liu, Y., J. Liu, K. S. Plante, J. A. Plante, X. Xie, X. Zhang, Z. Ku, Z. An, D. Scharton, C. Schindewolf,  
590 S. G. Widen, V. D. Menachery, P. Y. Shi, and S. C. Weaver. 2022. "The N501Y spike  
591 substitution enhances SARS-CoV-2 infection and transmission." *Nature* 602  
592 (7896):294-299. doi: 10.1038/s41586-021-04245-0.
- 593 Lobato, I. M., and C. K. O'Sullivan. 2018. "Recombinase polymerase amplification: Basics,  
594 applications and recent advances." *Trends Analyt Chem* 98:19-35. doi:  
595 10.1016/j.trac.2017.10.015.
- 596 Meng, B., S. A. Kemp, G. Papa, R. Datir, Iatm Ferreira, S. Marelli, W. T. Harvey, S. Lytras, A.  
597 Mohamed, G. Gallo, N. Thakur, D. A. Collier, P. Mlcochova, Covid- Genomics UK

- 598 Consortium, L. M. Duncan, A. M. Carabelli, J. C. Kenyon, A. M. Lever, A. De Marco, C.  
599 Saliba, K. Culap, E. Cameroni, N. J. Matheson, L. Piccoli, D. Corti, L. C. James, D. L.  
600 Robertson, D. Bailey, and R. K. Gupta. 2021. "Recurrent emergence of SARS-CoV-2 spike  
601 deletion H69/V70 and its role in the Alpha variant B.1.1.7." *Cell Rep* 35 (13):109292. doi:  
602 10.1016/j.celrep.2021.109292.
- 603 Munnink, B. B. O., N. Worp, D. F. Nieuwenhuijse, R. S. Sikkema, B. Haagmans, R. A. M. Fouchier,  
604 and M. Koopmans. 2021. "The next phase of SARS-CoV-2 surveillance: real-time molecular  
605 epidemiology." *Nature Medicine* 27 (9):1518-1524. doi: 10.1038/s41591-021-01472-w.
- 606 Nyberg, T., N. M. Ferguson, S. G. Nash, H. H. Webster, S. Flaxman, N. Andrews, W. Hinsley, J. L.  
607 Bernal, M. Kall, S. Bhatt, P. Blomquist, A. Zaidi, E. Volz, N. A. Aziz, K. Harman, S. Funk, S.  
608 Abbott, Covid- Genomics UK consortium, R. Hope, A. Charlett, M. Chand, A. C. Ghani, S.  
609 R. Seaman, G. Dabrera, D. De Angelis, A. M. Presanis, and S. Thelwall. 2022. "Comparative  
610 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron  
611 (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study." *Lancet*. doi:  
612 10.1016/S0140-6736(22)00462-7.
- 613 Oude Munnink, B. B., N. Worp, D. F. Nieuwenhuijse, R. S. Sikkema, B. Haagmans, R. A. M.  
614 Fouchier, and M. Koopmans. 2021. "The next phase of SARS-CoV-2 surveillance: real-time  
615 molecular epidemiology." *Nat Med* 27 (9):1518-1524. doi: 10.1038/s41591-021-01472-w.
- 616 Patchsung, M., K. Jantarug, A. Pattama, K. Aphicho, S. Suraritdechachai, P. Meesawat, K. Sappakhaw,  
617 N. Leelahakorn, T. Ruenkam, T. Wongsatit, N. Athipanyasilp, B. Eiamthong, B.  
618 Lakkanasirorat, T. Phoodokmai, N. Niljianskul, D. Pakotiprapha, S. Chanarat, A. Homchan,  
619 R. Tinikul, P. Kamutira, K. Phiwkaow, S. Soithongcharoen, C. Kantiwiriyawanitch, V.  
620 Pongsupasa, D. Trisrivirat, J. Jaroensuk, T. Wongnate, S. Maenpuen, P. Chaiyen, S.  
621 Kamnerdnakta, J. Swangsri, S. Chuthapisith, Y. Sirivatanauksorn, C. Chaimayo, R. Sutthent,  
622 W. Kantakamalakul, J. Joung, A. Ladha, X. Jin, J. S. Gootenberg, O. O. Abudayyeh, F.  
623 Zhang, N. Horthongkham, and C. Uttamapinant. 2020. "Clinical validation of a Cas13-based  
624 assay for the detection of SARS-CoV-2 RNA." *Nat Biomed Eng* 4 (12):1140-1149. doi:  
625 10.1038/s41551-020-00603-x.
- 626 Peto, T., and Uk Covid- Lateral Flow Oversight Team. 2021. "COVID-19: Rapid antigen detection for  
627 SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and  
628 specificity for mass-testing." *EClinicalMedicine* 36:100924. doi:  
629 10.1016/j.eclinm.2021.100924.
- 630 Piepenburg, O., C. H. Williams, D. L. Stemple, and N. A. Armes. 2006. "DNA detection using  
631 recombination proteins." *Plos Biology* 4 (7):1115-1121. doi: ARTN  
632 e20410.1371/journal.pbio.0040204.
- 633 Qian, J., S. A. Boswell, C. Chidley, Z. X. Lu, M. E. Pettit, B. L. Gaudio, J. M. Fajnzylber, R. T.  
634 Ingram, R. H. Ward, J. Z. Li, and M. Springer. 2020. "An enhanced isothermal amplification  
635 assay for viral detection." *Nat Commun* 11 (1):5920. doi: 10.1038/s41467-020-19258-y.
- 636 Tao, K., P. L. Tzou, J. Nouhin, R. K. Gupta, T. de Oliveira, S. L. Kosakovsky Pond, D. Fera, and R. W.  
637 Shafer. 2021. "The biological and clinical significance of emerging SARS-CoV-2 variants."  
638 *Nat Rev Genet* 22 (12):757-773. doi: 10.1038/s41576-021-00408-x.
- 639 Tegally, H., E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S.  
640 Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T.  
641 Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D.



642 Hardie, G. Marais, N. Y. Hsiao, S. Korsman, M. A. Davies, L. Tyers, I. Mudau, D. York, C.  
643 Maslo, D. Goedhals, S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik,  
644 C. K. Wibmer, B. T. Sewell, J. Lourenco, L. C. J. Alcantara, S. L. Kosakovsky Pond, S.  
645 Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C. Williamson, and T. de Oliveira. 2021.  
646 "Detection of a SARS-CoV-2 variant of concern in South Africa." *Nature* 592  
647 (7854):438-443. doi: 10.1038/s41586-021-03402-9.

648 Teng, F., L. Guo, T. Cui, X. G. Wang, K. Xu, Q. Gao, Q. Zhou, and W. Li. 2019. "CDetection:  
649 CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base  
650 specificity." *Genome Biol* 20 (1):132. doi: 10.1186/s13059-019-1742-z.

651 Villalva, C., C. Touriol, P. Seurat, P. Trempat, G. Delsol, and P. Brousset. 2001. "Increased yield of  
652 PCR products by addition of T4 gene 32 protein to the SMART PCR cDNA synthesis  
653 system." *Biotechniques* 31 (1):81-3, 86. doi: 10.2144/01311st04.

654 Vogels, C. B. F., M. I. Breban, I. M. Ott, T. Alpert, M. E. Petrone, A. E. Watkins, C. C. Kalinich, R.  
655 Earnest, J. E. Rothman, J. G. de Jesus, I. M. Claro, G. M. Ferreira, M. A. E. Crispim, L.  
656 Singh, H. Tegally, U. J. Anyaneji, E. B. Hodcroft, C. E. Mason, G. Khullar, J. Metti, J. T.  
657 Dudley, M. J. MacKay, M. Nash, J. H. Wang, C. Liu, P. Hui, S. Murphy, C. Neal, E. Laszlo,  
658 M. L. Landry, A. Muyombwe, R. Downing, J. Razeq, T. de Oliveira, N. R. Faria, E. C.  
659 Sabino, R. A. Neher, J. R. Fauver, N. D. Grubaugh, Brazil-UK CADDE Genomic Network,  
660 and Network Genomic Surveillance South. 2021. "Multiplex qPCR discriminates variants of  
661 concern to enhance global surveillance of SARS-CoV-2." *Plos Biology* 19 (5). doi: ARTN  
662 e300123610.1371/journal.pbio.3001236.

663 Wang, Y., Y. Zhang, J. Chen, M. Wang, T. Zhang, W. Luo, Y. Li, Y. Wu, B. Zeng, K. Zhang, R. Deng,  
664 and W. Li. 2021. "Detection of SARS-CoV-2 and Its Mutated Variants via  
665 CRISPR-Cas13-Based Transcription Amplification." *Anal Chem* 93 (7):3393-3402. doi:  
666 10.1021/acs.analchem.0c04303.

667

668 **Table 1. Comparison of RRCd with DETECTR and SHERLOCK for the**  
 669 **SARS-CoV-2 detection.**


	<b>RRCd</b>	<b>DETECTR</b> (Broughton et al. 2020)	<b>SHERLOCK</b> (Patchsung et al. 2020)
Target genes	<i>S, E and N</i>	<i>E and N</i>	<i>Orflab, S and N</i>
Assay procedures	RT-RPA (37 °C, 30 min); Cas12 reaction (37 °C, 30 min); Lateral flow strip (room temperature, 2 min)	RT-LAMP (62 °C, 20-30 min); Cas12 reaction (37 °C, 10 min); Lateral flow strip (room temperature, 2 min)	RT-RPA (42 °C, 25 min); T7 transcription and Cas13 reaction (37 °C, 30 min); Lateral flow strip (room temperature, 2 min)
Assay time	~ 60 min	~ 45 min	~ 60 min
LoD	10	20	42
Specificity	SNP and small deletion	NA	NA
RNA purification dependence	No	Yes	Yes

670 LoD, limit of detection (copies per reaction); NA, not applicable.

671 **Table 2. Predictive agreements of RRCd in detection of clinical samples.**

	RRCd results	RT-qPCR-verified positive samples		RT-qPCR-verified negative samples
		$C_t < 33$	$C_t \geq 33$	
<b>Fluorescence-based readout</b>	Positive	84 (true positive)	24 (true positive)	0 (false positive)
	Negative	1 (false negative)	13 (false negative)	82 (true negative)
	Total	85	37	82
	PPA/NPA	99%	65%	100%
	Total PPA/NPA	89%		100%
<b>Lateral-flow readout</b>	Positive	84 (true positive)	23 (true positive)	0 (false positive)
	Negative	1 (false negative)	14 (false negative)	82 (true negative)
	Total	85	37	82
	PPA/NPA	99%	62%	100%
	Total PPA/NPA	88%		100%

672 In total, 204 clinical samples including 122 positive samples and 82 negative  
 673 samples were analyzed by RRCd with both fluorescence-based and lateral-flow  
 674 readouts. PPA, positive predictive agreement; NPA, negative predictive agreement.



675

676 **Figure 1. Detection and discrimination of SARS-CoV-2 VOCs by RRCd.**

677 Schematic overview of RRCd workflow. (I) SARS-CoV-2 samples were released by

678 automatic extraction (~10 min) or using RNA release chemical agents without

679 extraction (~5 min). (II) The viral RNA was reverse transcribed into the dsDNA and

680 amplified by RPA. (III) Cas12a was guided to target the dsDNA by the specific

681 crRNA, thereby activated its *trans*-cleavage activity to the ssDNA probes in the

682 system. The results could be quantified by fluorescence detection of the cleaved

683 FQ-ssDNA (III a), or visualized by lateral-flow strip using the FB-ssDNA probe (III

684 b). RRCd in discrimination of SARS-CoV-2 VOCs with lateral-flow readout is

685 highlighted on the right panel. The target gene from SARS-CoV-2 variant was shown


686 as the template, and it was detected by either crRNA-VOC or crRNA-WT, leading to

687 the positive (upper right panel) or negative (lower right panel) test result,

688 respectively. dsDNA, double-strand DNA; ssDNA, single-strand DNA; FQ,

689 fluorophore (FAM)-quencher (BHQ1); FB, FITC-Biotin; PAM, protospacer adjacent

690 motif; VOC, variant of concern; WT, wild type; GNP, gold nanoparticle; gt, goat.



691

692 **Figure 2. The specificity of RRCd in detection of SARS-CoV-2 VOCs. A.**


693 Representative changes of amino acids in the spike protein in different SARS-CoV-2

694 VOCs. Data came from Outbreak.info (<https://outbreak.info/compare-lineages>) (Julia

695 L. Mullen 2021). The variations detected in this study are colored in red. A simple

696 model is shown on the right panel. Del, deletion. **B.** Specificity analysis of RRCd in

697 detection of SARS-CoV-2 *S* gene 501, using fluorescence-based readouts. The  
698 dsDNA derived from pseudovirus *S* gene N501 or Y501 was incubated with Cas12a,  
699 FQ-ssDNA, and distinct crRNA at 37 °C, and the corresponding fluorescence signal  
700 was recorded over 60 min (left panel) and quantified at 30 min (right panel). Data are  
701 presented as the mean ± S.D. (n = 3). \*\*\*,  $P < 0.01$  by student's *t* test. RNase-free  
702 water was used as the negative control (NC). RFU, relative fluorescence units. **C.**  
703 Specificity analysis of RRCd using lateral-flow readouts. The samples analyzed were  
704 the same as those in panel B. The reactions were conducted at 37 °C for 30 min before  
705 the mixtures were transferred onto the strips, using FB-ssDNA probe instead of  
706 FQ-ssDNA. The relative greyness (G) of strip bands was quantified using ImageJ. In  
707 this study,  $G_{\text{Sample}} / G_{\text{NC}}$  of the T band  $\geq 1.5$  indicates positive. **D, E.** Specificity  
708 analysis of RRCd in detection of SARS-CoV-2 *S* gene 478. **F, G.** Specificity analysis  
709 of RRCd in detection of SARS-CoV-2 *S* gene 69-70. **H.** Schematic of RRCd in  
710 detection of SARS-CoV-2 VOCs by Cas12a *cis*-cleavage activity. **I, J.** The specificity  
711 was demonstrated by PAGE analyses, using SARS-CoV-2 variants of N501Y and  
712  $\Delta$ H69-V70 as the examples.



713

714 **Figure 3. The detection limit of RRCd for SARS-CoV-2 VOCs.** The detection limit

715 of the targeted regions in VOCs were determined by using  $10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$ ,  $10^2$ ,


716 10 and 5 copies of pseudovirus RNA per reaction, respectively. The dsDNA derived

717 from the pseudovirus RNA was incubated with Cas12a, ssDNA probe, and crRNA at

718 37 °C for 60 min (fluorescence-based readouts) or 30 min (lateral-flow readouts),

719 respectively. The relative fluorescence intensity ( $F/F_0$ ) was calculated as the  
720 fluorescence signal versus the starting signal (left panel). Correspondingly, the  
721 fluorescence signal at the 30 min-reaction was quantified (middle panel). The positive  
722 samples of lateral-flow readouts (right panel) are indicated as blue by the T-line  
723 quantification as described. Data are presented as mean  $\pm$  S.D. from at least three  
724 independent experiments. For the dilutions with 10 and 5 copies per reaction, at least  
725 five independent experiments were conducted. **A.** LoD determination of RRCd for *E*  
726 gene. **B-E.** LoD determinations of RRCd for N501 (B), Y501 (C), T478 (D) and K478  
727 (E) in *S* gene, respectively. NC, negative control using the RNase-free water.






728

729 **Figure 4. Validation of RRCd in detection of 96 RT-qPCR-verified clinical**  
 730 **samples.** Nasopharyngeal and salivary swabs were collected from 20<sup>th</sup> January to 10<sup>th</sup>  
 731 April 2021 at Shanghai Customs, and a double-checked detection (*E* gene and *S* gene)  
 732 was executed for them by RRCd. To minimize the cognitive bias, all information of  
 733 the clinical samples was confidential to study staff before the detection. The results  
 734 are displayed according to the *C<sub>t</sub>* values of COVID-19 positive samples, and the total  
 735 number of clinical samples in each *C<sub>t</sub>* range are shown on the top of the panel.  
 736 Representatives of fluorescence-based readouts and lateral-flow readouts of the  
 737 positive samples as well as the negative samples are shown on the middle of the  
 738 panel. Both *E* gene and *S* gene (N510) were used as the targeted sequences in  
 739 fluorescence-based readouts. The light red and green indicate the positive detection  
 740 results of *E* gene and *S* gene (N501), respectively, while the orange represents the

741 double-checked positive result. The white indicates the negative result. Only the  
742 lateral-flow results of *E* gene are shown. +, positive; - , negative or indistinguishable.  
743 The analyses of the detection results are shown as the number of false negatives and  
744 the false-negative rate for each  $C_t$  range on the bottom of the panel. The SARS-CoV-2  
745 pseudovirus was used as the positive control. The full dataset is shown in  
746 Supplementary Figure 9.



747

748 **Figure 5. Validation of RRCd in detection and discrimination of 108**

749 **genome-sequencing-verified clinical samples. A. Discrimination of SARS-CoV-2 S**

750 **gene 501 variants in clinical samples. The total number of clinical samples in each C<sub>t</sub>**

751 **range are shown on the top of the panel. In total, 47 positive samples (C<sub>t</sub> range of**

752 **13-35) and 21 negative samples were detected. The S gene 501 variants were**

753 discriminated by crRNA-N501 (green) and crRNA-Y501 (light blue) using  
754 fluorescence-based readouts. In addition, the lateral-flow readouts are displayed in  
755 the middle of the panel using crRNA-N501 (left) and crRNA-Y501 (right). N, N501;  
756 Y, Y501; - , negative or indistinguishable. The analysis results are shown as the  
757 number of false discriminants and the false-discriminant rate for each  $C_t$  range on the  
758 bottom of the panel. **B.** Discrimination of SARS-CoV-2 *S* gene 478 variants in  
759 clinical samples. In total, 21 positive samples ( $C_t$  range of 17-34) and 19 negative  
760 samples were detected. The *S* gene 478 variants were discriminated by crRNA-T478  
761 (blue) and crRNA-K478 (pink) by fluorescence readouts. The lateral-flow readouts  
762 using crRNA\_T478 (left) and crRNA\_K478 (right) are displayed on the below. T,  
763 T478; K, K478; - , negative or indistinguishable. The corresponding SARS-CoV-2  
764 pseudoviruses were used as the positive controls. The full datasets for panel a and b  
765 are shown in Supplementary Figure 10 and Supplementary Figure 11, respectively.